ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation

Transfusion

Volumn 39, Issue 2, 1999, Pages 179-187

  Benjamin, Richard J ^a   McGurk, Siobhan ^b   Ralston, Maria S ^b   Churchill, W Hallowell ^b   Antin, Joseph H ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; ERYTHROCYTE APLASIA; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RECIPIENT; RETROSPECTIVE STUDY; STEM CELL; SURVIVAL RATE; THROMBOCYTE FUNCTION;

EID: 0032972697     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39299154733.x     Document Type: Article

References (43)

1. Buckner CD, Clift RA, Sanders JE, et al. ABO-incompatible marrow transplants. Transplantation 1978;26:233-8.
2. Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABO-incompatible marrow transplants. Transplantation 1982;33:427-9.
3. Gale RP, Feig S, Ho W, et al. ABO blood group system and bone marrow transplantation. Blood 1977;50:185-94.
4. Lasky LC, Warkentin PI, Kersey JH, et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion 1983;23:277-85.
5. Hows J, Beddow K, Gordon-Smith E, et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood 1986;67:177-81.
6. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990;75:290-5.
7. Sniecinski I, Henry S, Ritchey B, et al. Erythrocyte depletion of ABO-incompatible bone marrow. J Clin Apheresis 1985;2:231-4.
8. Blacklock HA, Gilmore MJ, Prentice HG, et al. ABO-incompatible bone-marow transplantation: removal of red blood cells from donor marrow avoiding recipient antibody depletion. Lancet 1982;2:1061-4.
9. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988;45:530-4.
10. Tichelli A, Gratwohl A, Wenger R, et al. ABO-incompatible bone marrow transplantation: in vivo adsorption, an old forgotten method. Transplant Proc 1987;19:4632-7.
11. Or R, Naparstek E, Mani N, Slavin S. Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Two case reports with successful resonse to plasmapheresis. Transpl Int 1991;4:99-102.
12. Mehta J, Powles R, Singhal S, et al. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Bone Marrow Transplant 1996;18:151-6.
13. Mehta J, Powles R, Horton C, et al. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Bone Marrow Transplant 1995;15:853-8.
14. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226-35.
15. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis 1994;9:1-5.
16. Metcalfe P, Williamson LM, Reutelingsperger CP, et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98:86-95.
17. Vengelen-Tyler V, ed. Technical manual. 12th ed. Bethesda: American Association of Blood Banks, 1996.
18. Preti RA, Ahmed T, Ciavarella D. Comparison of the Cobe 2991 cell washer and the Haemonetics V50 apheresis system for automated bone marrow processing (abstract). Proc Annu Meet Am Assoc Cancer Res 1991;32:A1016.
19. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991;78:2139-49.
20. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
21. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70:1382-8.
22. Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997;20:737-43.
23. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993;329:1225-30.
24. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996;88:3634-41.
25. Bensinger W, Petersen FB, Banaji M, et al. Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission. Bone Marrow Transplant 1989;4:409-14.
26. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-63.
28. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-91.
29. Bensinger WI, Buckner CD, Clift RA, et al. Comparison of techniques for dealing with major ABO-incompatible marrow transplants. Transplant Proc 1987;19:4605-8.
30. Webb IJ, Soiffer RJ, Andersen JW, et al. In vivo adsorption of isoagglutinins prior to major ABO incompatible bone marrow transplantation. Biol Blood Marrow Transplant 1997;3:267-72.
31. Bacigalupo A, Van Lint MT, Occhini D, et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988;45:1091-4.
32. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukeamia. Br J Haematol 1996;93:59-67.
33. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 1985;25:60-2.
34. Conway LT, Scott EP. Acute hemolytic transfusion reaction due to ABO incompatible plasma in a plateletapheresis concentrate (letter). Transfusion 1984;24:413-4.
35. Ferguson DJ. Acute intravascular hemolysis after a platelet transfusion. CMAJ 1988;138:523-4.
36. Shanwell A, Ringden O, Wiechel B, et al. A study of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991;60:23-7.
37. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-30.
38. Castenskiold EC, Kelsey SM, Collins PW, et al. Functional hyperactiviry of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse. Bone Marrow Transplant 1995;15:879-84.
39. Davenport RD, Burdick M, Moore SA, Kunkel SL. Cytokine production in IgG-mediated red cell incompatibility. Transfusion 1993;33:19-24.
40. Davenport RD, Stricter RM, Standiford TJ, Kunkel SL. Interleukin-8 production in red blood cell incompatibilty. Blood 1990;76:2439-42.
41. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
42. Heddle NM, Klama L, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
43. Duhrsen U, Hossfeld DK. Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol 1996;73:53-70.